Emergence of streptococcus pneumoniae serotype 12F after sequential introduction of 7- and 13-valent vaccines, Israel

Assaf Rokney, Shalom Ben-Shimol, Zinaida Korenman, Nurith Porat, Zeev Gorodnitzky, Noga Givon-Lavi, Merav Ron, Vered Agmon, Ron Dagan, Lea Valinsky

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Israel implemented use of 7- and 13-valent pneumococcal vaccine in 2009 and 2010, respectively. We describe results of prospective, population-based, nationwide active surveillance of Streptococcus pneumoniae serotype 12F (Sp12F) invasive pneumococcal disease (IPD) dynamics in the 7 years after vaccine introduction. Of 4,573 IPD episodes during July 2009–June 2016, a total of 434 (9.5%) were caused by Sp12F. Sp12F IPD rates (cases/100,000 population) increased in children <5 years of age, from 1.44 in 2009–2010 to >3.9 since 2011–2012, followed by an increase in all ages. During 2011–2016, Sp12F was the most prevalent IPD serotype. Sp12F isolates were mostly penicillin nonsusceptible (MIC >0.06 µg/mL; MIC50 = 0.12) and predominantly of sequence type 3774), a clone exclusively found in Israel (constituting ≈90% of isolates in 2000–2009). The sharp increase, long duration, and predominance of Sp12F IPD after vaccine implementation reflect a single clone expansion and may represent more than a transient outbreak.

Original languageEnglish
Pages (from-to)453-461
Number of pages9
JournalEmerging Infectious Diseases
Volume24
Issue number3
DOIs
StatePublished - 1 Mar 2018

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Emergence of streptococcus pneumoniae serotype 12F after sequential introduction of 7- and 13-valent vaccines, Israel'. Together they form a unique fingerprint.

Cite this